Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

Novo Nordisk’s ($NVO) shares in Copenhagen closed roughly 5% higher on Friday. This came after Nordea ($NRDBY) went bullish on the Danish drugmaker...

Novo Nordisk Stock Climbs as Analyst Flags Potential for More Wegovy Pill Sales

Danish drugmaker Novo Nordisk’s ($NVO) shares in Copenhagen rose about 5% on Friday. This coincides with Novo Nordisk Foundation, the company’s maj...

Novo Nordisk Stock Jumps as Owner Launches Obesity Research Network

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is running a Phase 3 trial called “A ...

Lilly’s Lepodisiran Trial Targets Lp(a) as a New Front in Heart Risk

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study, officially titled “A Randomized, Placebo-Controlled, P...

Retatrutide Trial Completion Signals Next Step for Eli Lilly’s Diabetes Pipeline

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The latest update from Eli Lilly and Company highlights a complet...

Eli Lilly’s Mevidalen Alzheimer’s Trial Reaches Completion: What Investors Should Watch

ARK’s daily trade report for June 17 showed Cathie Wood moving capital across several high-profile names. The firm trimmed positions in Robinhood M...

LLY, COIN, HOOD, and ROKU Stocks in Focus: Cathie Wood Sells Winners and Buys New Catalysts — 6/18/26

WSW, NY, June 17th, 2026, FinanceWire Rhythm&rsquo;s latest rare-obesity win strengthens the MC4R thesis – making Palatin&rsquo;s more selective, n...

Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly And Company (LLY) is launching a Phase 2 study called T...

Lilly Expands Donanemab Ambitions With New Lewy Body Dementia Trial

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 2a single‑arm Eli Lilly study, officially titled “A Pha...

Eli Lilly Halts Mid‑Stage Rheumatoid Arthritis Trial: What It Means for LLY Investors

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly And Company has completed a Phase 3b trial called “Effi...

Lilly’s TOGETHER-PsO Trial: A New Push To Link Psoriasis And Obesity Treatment

The company has experimented with pain medicines in the past. 


M&A News: Eli Lilly (LLY) Expands Into Painkiller Market with Latest Acquisition

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is running a first‑in‑human trial cal...

Eli Lilly Advances New Early‑Stage Drug With Fresh Clinical Trial Update

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is running a Phase 1 study called “A ...

Eli Lilly Advances LY4395089 With New Drug–Drug Interaction Study

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study “A Phase 1, Open Label, Multiple-Dose Study to Assess t...

Eli Lilly Advances New Alzheimer’s Drug LY3439539 Into Phase 1: What Investors Should Watch

Eli Lilly Advances New Oral Candidate With Fresh Phase 1 Bioavailability Study

Dell Technologies ($DELL) stock has pulled back from its record high of $469.47 on June 1. However, its artificial intelligence (AI) backlog contin...

DELL Stock Pulled Back. The AI Backlog Keeps Building

The Strategy Shares Monopoly ETF (MPLY) is an actively managed fund that owns the U.S. equities Strategy Shares believes demonstrate durable compet...

Ten Structural Traits That Define a Monopoly: Inside the Screen Behind the Strategy Shares Monopoly ETF (MPLY)

Novo Nordisk ($NVO) is stepping up its competition with rival Eli Lilly ($LLY) in China’s oral weight loss drug market. According to a Reuters repo...

Novo Nordisk Seeks China Approval for Wegovy Pill, Intensifying Rivalry with Lilly

Barclays analyst Emily Field maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,400.00. Field covers the Healthcare secto...

Eli Lilly & Co (LLY) Gets a Buy from Barclays

Most Americans have health insurance through their employer. 


Eli Lilly Stock (LLY) Dips on Reports Employers Plan to Drop Weight-Loss Drug Coverage

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY), Insulet (PODD) and Novartis ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Insulet (PODD) and Novartis (NVS)

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study “Randomized, Placebo-Controlled, Phase 2 Clinical Trial...

Eli Lilly Launches New Phase 2 Bet on Chronic Low Back Pain Relief

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. (LLY) has launched a Phase 2 trial called “Rand...

Eli Lilly Expands Chronic Pain Pipeline With New Osteoarthritis Trial

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. has begun a Phase 3 trial called “A Study of Br...

Lilly’s Brenipatide Trial Targets Depression Relapse, Opening a New Long-Term Growth Path

Using the&nbsp;TipRanks Stock Screener Tool, we identified three companies that have low&nbsp;Price-to-Earnings (P/E) ratios&nbsp;and hold a “Stron...

3 Best Low P/E Stocks Rated ‘Strong Buy’ with Over 20% Upside

In a report released today, from Ord Minnett maintained a Hold rating on CSL, with a price target of A$117.00. In addition to Ord Minnett, CSL also...

Ord Minnett Keeps Their Hold Rating on CSL (CMXHF)

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. This Phase 1 study, officially titled “A Phase 1, Open-label Stud...

Lilly Advances Early-Stage Asset With Completion of LY4064809 Bioavailability Study

The pharma giant is looking to extend its lead in the obesity drug market. 


Eli Lilly Stock (LLY) Jumps 4%. The Outlook for Its Weight-Loss Drugs Just Keeps Getting Better

Eli Lilly (NYSE:LLY) shares are getting the thumbs up from investors on Monday after new data on its next-generation obesity therapy retatrutide st...

‘This Is Compelling’: Citi Pounds the Table on Eli Lilly (LLY) Stock

Eli Lilly and Company ($LLY) gave investors another reason to watch its obesity pipeline after new late-stage data showed that its experimental dru...

Eli Lilly’s Retatrutide Gives LLY Stock a Fresh Obesity Drug Catalyst

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY), Cytokinetics (CYTK) and Doximi...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) has launched a Phase 2b trial called ...

Lilly Expands Obesity Pipeline With New Phase 2b Macupatide–Eloralintide Trial

The company recently launched a new pill version of its weight-loss drug. 


Jim Cramer Sees Eli Lilly (LLY) Delivering ‘Knockout Punch’ to Competitors

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 3b ATTAIN-MAINTAIN trial from Eli Lilly and Company tes...

Lilly’s ATTAIN-MAINTAIN Trial: A Fresh Pill-Based Play in the Obesity Market

Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on Holley (HLLY) and Victoria’s Secret (VSXY). Holley (HLLY) ...

Analysts Offer Insights on Consumer Cyclical Companies: Holley (HLLY) and Victoria’s Secret (VSXY)

In a report released on June 2, David Risinger from Leerink Partners reiterated a Buy rating on Eli Lilly & Co. The company’s shares closed yesterd...

Leerink Partners Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

The company has been on a buying spree this year. 


‘Expect More Acquisitions,’ Says Eli Lilly’s (LLY) Top Dealmaker

Ord Minnett analyst maintained a Hold rating on CSL today and set a price target of A$117.00. In addition to Ord Minnett, CSL also received a Hold ...

Ord Minnett Remains a Hold on CSL (CMXHF)

The medication treats bowel conditions. 


Eli Lilly Signs Licensing Deal for Intestinal Treatment

Indications are that the new weight-loss pill is selling well. 


Eli Lilly Stock (LLY) Gets a Price Target Boost as Weight-Loss Drug Sales Accelerate

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Teva Pharmaceutical (TEVA), Thermo Fisher (TMO) and ...

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Thermo Fisher (TMO) and Eli Lilly & Co (LLY)

The stock market’s $1 trillion club just got more crowded, and the newest members tell investors something important about where the AI trade is mo...

Beyond Nvidia: Micron, SK Hynix and the AI Stocks Reshaping the $1 Trillion Club

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacific Edge Limited (PFGTF), Kura Oncology (KURA)...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacific Edge Limited (OtherPFGTF), Kura Oncology (KURA) and Eli Lilly & Co (LLY)

The company has been on a buying spree lately. 


Eli Lilly Stock (LLY) Climbs Higher on News of $4 Billion Acquisition Spree

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Praxis Precision Medicines (PRAX) and Eli Lilly & Co...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX) and Eli Lilly & Co (LLY)

Holley ( ($HLLY) ) has issued an announcement. On May 26, 2026, Holley Inc. announced that its Board of Directors approved a share repurchase progr...

Holley Board Authorizes $25 Million Share Repurchase Program

In a report released on May 24, David Bailey from Morgan Stanley reiterated a Buy rating on CSL, with a price target of $166.00. According to TipRa...

CSL (CMXHF) Receives a Buy from Morgan Stanley

Bristol Gate Capital Partners Inc., managed by Richard Hamm, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). ...

Bristol Gate Capital trims Eli Lilly stake by 4,966 shares

Mirova US LLC, managed by Philippe Zaouati, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The hedge fund re...

Mirova US LLC Cuts Eli Lilly Stake by 15,836 Shares

ARK Investment Management LLC, managed by Cathie Wood, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The he...

ARK Investment’s Cathie Wood boosts Eli Lilly stake by 12,676 shares

Graham Capital Management, L.P., managed by Kenneth Tropin, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). T...

Graham Capital Management Boosts Eli Lilly Stake by 1,869 Shares

Ardsley Advisory Partners, managed by Philip Hempleman, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The h...

Ardsley Advisory Partners Cuts 35,000 Eli Lilly Shares

Chilton Investment Co LLC, managed by Richard Chilton, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The he...

Chilton Investment Trims Eli Lilly Stake, Sells 4,088 Shares

Moore Capital Management LP, managed by Louis Moore Bacon, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). Th...

Moore Capital trims Eli Lilly stake, sells 11,000 shares

Mairs & Power Inc, managed by Bill Frels, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The hedge fund redu...

Mairs & Power Inc Cuts Eli Lilly Stake by 19,039 Shares

Bridgewater Associates, LP, managed by Ray Dalio, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The hedge f...

Bridgewater Associates, LP Trims Eli Lilly Stake by 2,480 Shares

Woodline Partners LP, managed by Michael Rockefeller, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The hed...

Woodline Partners LP Boosts Eli Lilly Stake by 17,612 Shares

PRIMECAP Management Co, managed by Theofanis Kolokotrones, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). Th...

PRIMECAP Management Co trims Eli Lilly stake by 42K shares

Gamco Investors, Inc. ET AL, managed by Mario Gabelli, recently executed a significant transaction involving Eli Lilly And Company (($LLY)). The he...

Gamco Investors’ Mario Gabelli Boosts Eli Lilly Stake

Eli Lilly & Co ( ($LLY) ) has risen by 7.78%. Read on to learn why. Eli Lilly & Co shares climbed 7.78% over the past week as investors focused


Eli Lilly & Co Surges on Powerful Pipeline Hopes

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company (LLY) has launched a Phase ...

Eli Lilly Expands Heart Failure Pipeline With New Phase 1 Trial of LY3971297

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Edwards Lifesciences (EW) and Eli Lilly & Co (LLY) w...

Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Eli Lilly & Co (LLY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and IN8bio (INAB) with bullish ...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and IN8bio (INAB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY) and Arvinas Holding Company (AR...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arvinas Holding Company (ARVN)

Eli Lilly stock still has major upside potential, according to one top analyst.


How High Can Eli Lilly’s Stock (LLY) Price Go?

The company has a growing number of obesity medications. 


Eli Lilly’s (LLY) Next-Generation Weight-Loss Drug Clears Big Hurdle

Using the TipRanks Stock Screener Tool, we identified three companies that have low Price-to-Earnings (P/E) ratios and hold a “Strong Buy” consensu...

3 ‘Strong Buy’ Low P/E Stocks with Over 20% Upside

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eli Lilly & Co (LLY), Zai Lab (ZLAB) and NanoViricides (NNVC). El...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Zai Lab (ZLAB) and NanoViricides (NNVC)

Eli Lilly & Co ( ($LLY) ) has provided an update. On May 20, 2026, Eli Lilly and Company completed a multibillion-dollar debt offering, issuing a m...

Market Cap	$788.86B	P/E Ratio	30.69
52W High	$1,182.73	52W Low	$623.78
Div Yield	692.0%	Payout Ratio	22.1%
EPS Growth 3Y	49.2%	52W Position	84.9%
Overall Score	69	Value Score	45
Quality Score	71	Technical Score	91

EPS Current Est	$35.8	EPS Next Est	$44.6
EPS Growth Est	+24.6%	DPS Growth 3Y	16.7%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LLY	$1,098.57	-1.21%	4.47M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LLY	$1,098.57	-1.2%	4.47M
3
4
5
6

LLY

LLY

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Eli Lilly and Company Data in Excel

Get Eli Lilly and Company Data in Excel